Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical's GHG Emissions Data Preview
In 2023, Kobayashi Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
However, Kobayashi Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Kobayashi Pharmaceutical's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Kobayashi Pharmaceutical amounted to 24,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
0Kobayashi Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Kobayashi Pharmaceutical's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Kobayashi Pharmaceutical were 6,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Kobayashi Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Kobayashi Pharmaceutical's Scope 1 emissions have decreased by 14.29%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Kobayashi Pharmaceutical's Scope 1 emissions remained relatively stable, indicating that Kobayashi Pharmaceutical's emissions have plateaued with no significant change in its operational footprint.
What are Kobayashi Pharmaceutical's Scope 2 emissions?
In 2023, Kobayashi Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 18,000 tCOâ‚‚e using the market-based method.
Has Kobayashi Pharmaceutical reduced its Scope 2 emissions over time?
Since 2018, Kobayashi Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 21.74%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Kobayashi Pharmaceutical's Scope 2 emissions (Market-Based) have remained relatively stable, indicating that Kobayashi Pharmaceutical 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Kobayashi Pharmaceutical use for Scope 2 reporting?
In 2023, Kobayashi Pharmaceutical reported its Scope 2 emissions using the market-based method.
Kobayashi Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
Insights into Kobayashi Pharmaceutical's Value Chain Emissions
In 2023, Kobayashi Pharmaceutical reported 559,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Kobayashi Pharmaceutical includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Kobayashi Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Kobayashi Pharmaceutical's Scope 3 emissions?
In 2023, Kobayashi Pharmaceutical reported total Scope 3 emissions of 559,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Kobayashi Pharmaceutical reduced its Scope 3 emissions over time?
Since 2018, Kobayashi Pharmaceutical's Scope 3 emissions have remained relatively stable, indicating that Kobayashi Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint.
Compared to the previous year (2022), Kobayashi Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Kobayashi Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint.
Insights into Kobayashi Pharmaceutical's Total Carbon Footprint
In 2023, Kobayashi Pharmaceutical reported a total carbon footprint of 583,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 6.19% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Kobayashi Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.88% of the company's total carbon footprint, followed by Scope 2 emissions at 3.09%.